Sun Pharma posts double-digit Q1 growth as India business jumps 16%

Sun Pharmaceutical, led by founder-chairman Dilip Shanghvi, reported consolidated revenue growth of about 10% year-on-year for the first quarter of FY27, with its India formulation business up 16% and global innovative medicines up nearly 13%, according to Business Today. The company kept EBITDA margins near 29% and said its pending Organon acquisition remains on track to close in the fourth quarter of FY27.